School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, Leicestershire LE11 3TU, UK.
CDL Research, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; Department of Experimental Cardiology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Adv Drug Deliv Rev. 2021 Jun;173:479-491. doi: 10.1016/j.addr.2021.04.012. Epub 2021 Apr 20.
Extracellular vesicles (EVs) are complex nanoparticles required for the intercellular transfer of diverse biological cargoes. Unlike synthetic nanoparticles, EVs may provide a natural platform for the enhanced targeting and functional transfer of therapeutics across complex and often impenetrable biological boundaries (e.g. the blood-brain barrier or the matrix of densely organised tumours). Consequently, there is considerable interest in utilising EVs as advanced drug delivery systems for the treatment of a range of challenging pathologies. Within the past decade, efforts have focused on providing standard minimal requirements for conducting basic EV research. However, no standard reporting framework has been established governing the therapeutic loading of EVs for drug delivery applications. The purpose of this review is to critically evaluate progress in the field, providing an initial set of guidelines that can be applied as a benchmark to enhance reproducibility and increase the likelihood of translational outcomes.
细胞外囊泡(EVs)是一种复杂的纳米颗粒,对于不同生物货物的细胞间转移是必需的。与合成纳米颗粒不同,EVs 可能为治疗剂的增强靶向和功能转移提供一个天然平台,跨越复杂且通常难以穿透的生物边界(例如血脑屏障或致密组织肿瘤的基质)。因此,人们对利用 EVs 作为治疗一系列挑战性病理的先进药物输送系统非常感兴趣。在过去的十年中,人们致力于为进行基本 EV 研究提供标准的最低要求。然而,尚未建立用于药物输送应用的 EV 治疗性加载的标准报告框架。本综述的目的是批判性地评估该领域的进展,提供一组初始指南,可作为基准加以应用,以提高可重复性并增加转化结果的可能性。